BCL2 and cancer: Given various studies demonstrating that TRAIL therapy may be synergistic with Bcl-2 inhibitors and SMAC mimetics51,52, we believe that there is a clear rationale for further investigation into combination therapies with TRAIL-Trimer to further potentiate apoptosis in cancer cells.